Cargando…
Antiviral peptides as promising therapeutic drugs
While scientific advances have led to large-scale production and widespread distribution of vaccines and antiviral drugs, viruses still remain a major cause of human diseases today. The ever-increasing reports of viral resistance and the emergence and re-emergence of viral epidemics pressure the hea...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079787/ https://www.ncbi.nlm.nih.gov/pubmed/31101936 http://dx.doi.org/10.1007/s00018-019-03138-w |
_version_ | 1783507892215742464 |
---|---|
author | Vilas Boas, Liana Costa Pereira Campos, Marcelo Lattarulo Berlanda, Rhayfa Lorrayne Araujo de Carvalho Neves, Natan Franco, Octávio Luiz |
author_facet | Vilas Boas, Liana Costa Pereira Campos, Marcelo Lattarulo Berlanda, Rhayfa Lorrayne Araujo de Carvalho Neves, Natan Franco, Octávio Luiz |
author_sort | Vilas Boas, Liana Costa Pereira |
collection | PubMed |
description | While scientific advances have led to large-scale production and widespread distribution of vaccines and antiviral drugs, viruses still remain a major cause of human diseases today. The ever-increasing reports of viral resistance and the emergence and re-emergence of viral epidemics pressure the health and scientific community to constantly find novel molecules with antiviral potential. This search involves numerous different approaches, and the use of antimicrobial peptides has presented itself as an interesting alternative. Even though the number of antimicrobial peptides with antiviral activity is still low, they already show immense potential to become pharmaceutically available antiviral drugs. Such peptides can originate from natural sources, such as those isolated from mammals and from animal venoms, or from artificial sources, when bioinformatics tools are used. This review aims to shed some light on antimicrobial peptides with antiviral activities against human viruses and update the data about the already well-known peptides that are still undergoing studies, emphasizing the most promising ones that may become medicines for clinical use. |
format | Online Article Text |
id | pubmed-7079787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-70797872020-03-23 Antiviral peptides as promising therapeutic drugs Vilas Boas, Liana Costa Pereira Campos, Marcelo Lattarulo Berlanda, Rhayfa Lorrayne Araujo de Carvalho Neves, Natan Franco, Octávio Luiz Cell Mol Life Sci Review While scientific advances have led to large-scale production and widespread distribution of vaccines and antiviral drugs, viruses still remain a major cause of human diseases today. The ever-increasing reports of viral resistance and the emergence and re-emergence of viral epidemics pressure the health and scientific community to constantly find novel molecules with antiviral potential. This search involves numerous different approaches, and the use of antimicrobial peptides has presented itself as an interesting alternative. Even though the number of antimicrobial peptides with antiviral activity is still low, they already show immense potential to become pharmaceutically available antiviral drugs. Such peptides can originate from natural sources, such as those isolated from mammals and from animal venoms, or from artificial sources, when bioinformatics tools are used. This review aims to shed some light on antimicrobial peptides with antiviral activities against human viruses and update the data about the already well-known peptides that are still undergoing studies, emphasizing the most promising ones that may become medicines for clinical use. Springer International Publishing 2019-05-17 2019 /pmc/articles/PMC7079787/ /pubmed/31101936 http://dx.doi.org/10.1007/s00018-019-03138-w Text en © Springer Nature Switzerland AG 2019 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Vilas Boas, Liana Costa Pereira Campos, Marcelo Lattarulo Berlanda, Rhayfa Lorrayne Araujo de Carvalho Neves, Natan Franco, Octávio Luiz Antiviral peptides as promising therapeutic drugs |
title | Antiviral peptides as promising therapeutic drugs |
title_full | Antiviral peptides as promising therapeutic drugs |
title_fullStr | Antiviral peptides as promising therapeutic drugs |
title_full_unstemmed | Antiviral peptides as promising therapeutic drugs |
title_short | Antiviral peptides as promising therapeutic drugs |
title_sort | antiviral peptides as promising therapeutic drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079787/ https://www.ncbi.nlm.nih.gov/pubmed/31101936 http://dx.doi.org/10.1007/s00018-019-03138-w |
work_keys_str_mv | AT vilasboaslianacostapereira antiviralpeptidesaspromisingtherapeuticdrugs AT camposmarcelolattarulo antiviralpeptidesaspromisingtherapeuticdrugs AT berlandarhayfalorraynearaujo antiviralpeptidesaspromisingtherapeuticdrugs AT decarvalhonevesnatan antiviralpeptidesaspromisingtherapeuticdrugs AT francooctavioluiz antiviralpeptidesaspromisingtherapeuticdrugs |